Type 2 & other diabetes

The relative and combined ability of stress hyperglycemia ratio and N-terminal pro-B-type natriuretic peptide to predict all-cause mortality in diabetic patients with multivessel coronary artery disease

Cardiovasc DiabetolPublished Cohort study

Main finding · All-cause mortalityResult — go to the resultHazard ratio 12.244 95% CI 5.828–25.721

Authors' conclusion

SHR and NT-proBNP independently and jointly predicted all-cause mortality in diabetic patients with MVD, suggesting that strategies to improve risk stratification in these patients should incorporate SHR and NT-porBNP into risk algorithms.

Study context

Population
Diabetic patients with multivessel coronary artery disease (CAD) who underwent coronary angiography at Tianjin Chest Hospital, January–December 2016138 died
Participants
1,148 patients
Exposure
Stress hyperglycemia ratio (SHR) and NT-proBNP levels for prediction of all-cause mortality
Outcome
All-cause mortality
Follow-up
Mean 4.2 year
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Hazard ratio

12.244

95% CI 5.828–25.721

P < 0.001

SHR-H and NT-proBNP-Hvs SHR-L and NT-proBNP-L
HR 12.244 (95% CI 5.828–25.721); P < 0.001

Observational data: associations, not effects.

Further findings

Discrimination for all-cause mortality

AUC, SHR
0.615
AUC, NT-proBNP
0.699
Adding either marker to original models significantly improved C-statistic and integrated discrimination improvement (all P < 0.05)
Combining SHR and NT-proBNP into the original model provided maximal prognostic information

Original publication

The relative and combined ability of stress hyperglycemia ratio and N-terminal pro-B-type natriuretic peptide to predict all-cause mortality in diabetic patients with multivessel coronary artery disease. Cardiovasc Diabetol. Published 11 March 2024. doi:10.1186/s12933-024-02186-2

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.